Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors

被引:6
|
作者
Ruiz Castro, Beatriz Guerreiro [1 ]
Souza, Cristiano de Padua [2 ]
Mattos da Cunha Andrade, Carlos Eduardo [3 ]
Vieira, Marcelo de Andrade [3 ]
Pinto de Andrade, Diocesio Alves [4 ]
dos Reis, Ricardo [3 ]
机构
[1] Fac Ciencias Saude Barretos Dr Paulo Prata, Barretos, SP, Brazil
[2] Hosp Canc Barretos, Gynecol Clin Oncol Dept, Barretos, SP, Brazil
[3] Hosp Canc Barretos, Gynecol Oncol Dept, Barretos, SP, Brazil
[4] Inst Oncol Ribeirao Preto, InORP ONCOCLIN Grp, Ribeirao Preto, SP, Brazil
来源
REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA | 2019年 / 41卷 / 07期
关键词
ovarian neoplasms; Sertoli-Leydig cell tumor; oncologic prognosis; CORD-STROMAL TUMORS; CLINICOPATHOLOGICAL ANALYSIS; HYPERESTROGENISM; MANAGEMENT;
D O I
10.1055/s-0039-1693056
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Cancer de Barretos, Barretos, state of Sao Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presented with virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 UAL), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (beta-hCG) was 0.6 mUl/ml (0.0-2.3 mUl(ml), carcinoem-bryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopa-thological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation of Gynecology and Obstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of them underwent 3 cycles of paclitaxel and carboplatin every 21 days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.
引用
收藏
页码:440 / 448
页数:9
相关论文
共 50 条
  • [31] Ovarian Sertoli-Leydig tumor: A tricky tumor
    Brandone, Nicolas
    Borrione, Claude
    Rome, Angelique
    de Paula, Andre Maues
    ANNALES DE PATHOLOGIE, 2018, 38 (02) : 131 - 136
  • [32] 18 Sertoli-leydig cell tumors of the ovary: analysis of a single institution database
    Li, Wei
    Yang, Shuli
    Su, Li
    Miao, Jinwei
    Wu, Yumei
    Zheng, Xingzheng
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2022, 43 (03) : 134 - 140
  • [33] Review on Sertoli-Leydig Cell Tumours of the Ovary
    Muscat, Corinne
    Calleja-Agius, Jean
    DISCOVERY MEDICINE, 2024, 36 (181) : 234 - 247
  • [34] Laparoscopic management of Sertoli-Leydig cell tumors of the ovary -: A report of two cases
    Kriplani, A
    Agarwal, N
    Roy, KK
    Manchanda, R
    Singh, MK
    JOURNAL OF REPRODUCTIVE MEDICINE, 2001, 46 (05) : 493 - 496
  • [35] OVARIAN SERTOLI-LEYDIG CELL TUMOR: A RARE TUMOR WITH ATYPICAL PRESENTATION
    Nayak, Prasanta Kumar
    Mitra, Subarna
    Mathew, Agnes
    Ramakrishnan, Poornima
    Padhi, Somanath
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2013, 2 (03): : 265 - 270
  • [36] Ovarian Sertoli-Leydig cell tumour with rhabdomyosarcoma and borderline mucinous neoplasm
    Chougule, Abhijit
    Singh, Priya
    Saha, Pradip Kumar
    Dey, Pranab
    PATHOLOGY, 2016, 48 (03) : 278 - 281
  • [37] Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients
    Akman, Levent
    Ertas, Ibrahim Egemen
    Gokcu, Mehmet
    Terek, Mustafa Cosan
    Sanci, Muzaffer
    Sanli, Ulus Ali
    Zekioglu, Osman
    Ozsaran, Ahmet Aydin
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 290 - 294
  • [38] DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors
    Karnezis, Anthony N.
    Wang, Yemin
    Keul, Jacqueline
    Tessier-Cloutier, Basile
    Magrill, Jamie
    Kommoss, Stefan
    Senz, Janine
    Yang, Winnie
    Proctor, Lily
    Schmidt, Dietmar
    Clement, Philip B.
    Gilks, C. Blake
    Huntsman, David G.
    Kommoss, Friedrich
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (05) : 628 - 638
  • [39] Ovarian Sertoli-Leydig and granulosa cell tumor: comparison of epidemiology and survival outcomes
    Dimitrios Nasioudis
    Spyridon A. Mastroyannis
    Ashley F. Haggerty
    Emily M. Ko
    Nawar A. Latif
    Archives of Gynecology and Obstetrics, 2020, 302 : 481 - 486
  • [40] The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors
    Wang, Yemin
    Chen, Jiamin
    Yang, Winnie
    Mo, Fan
    Senz, Janine
    Yap, Damian
    Anglesio, Michael S.
    Gilks, Blake
    Morin, Gregg B.
    Huntsman, David G.
    NEOPLASIA, 2015, 17 (08): : 650 - 660